Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhIL-15 and Obinutuzumab in R/R CLL
NCT03759184Phase 1Terminated
- Sponsor
- National Cancer Institute
- Start
- Jul 2019
- Primary completion
- Dec 2019
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 1, open-label trial of recombinant human interleukin-15 in chronic lymphocytic leukemia (CLL) (2 arms), sponsored by National Cancer Institute. Primary endpoints: Number of Treatment-emergent Adverse Events Related to rhIL-15 at 28 days, Number of Treatment-emergent Adverse Events Related to Obinutuzumab at 28 days and 4 more. Started Jul 2019; status: terminated.
02
Drugs
recombinant human interleukin-15
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT03759184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03759184.